SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.
Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, Miyoshi K, Kishigami S, Ueno T, Iwatani Y, Suzuki T, Tokunaga K. · 2021
Read SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. by Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, Miyoshi K, Kishigami S, Ueno T, Iwatani Y, Suzuki T, Tokunaga K. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7870668.txt.
Introduction
Ozono and co-authors show that the D614G spike change helps SARS-CoV-2 enter cells more easily. The virus keeps mutating as it spreads. Spike changes can alter entry through ACE2. Whether they did so was unknown. The team tested natural spike variants.
A test virus with the parent spike entered cells poorly. The D614G form entered best of all variants tried. Shape and binding tests explained the gain. The changed spike grips ACE2 more tightly. Patient sera still neutralized it just as well, though. Entry gain thus came without immune escape. The authors call for world tracking of such changes. Spread risk turns on traits like this one.
Catalog record
| CREATOR | Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, Miyoshi K, Kishigami S, Ueno T, Iwatani Y, Suzuki T, Tokunaga K. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity By Seiya Ozono, Yanzhao Zhang, Hirotaka Ode, Kaori Sano, Toong Seng Tan, Kazuo Imai, Kazuyasu Miyoshi, Satoshi Kishigami, Takamasa Ueno, Yasumasa Iwatani, Tadaki Suzuki, Kenzo Tokunaga Published in: Nature Communications DOI: 10.1038/s41467-021-21118-2 ABSTRACT Abstract The causative agent of the COVID-19 pandemic, SARS-CoV-2, is steadily mutating during continuous transmission among humans. Such mutations can occur in the spike (S) protein that binds to the ACE2 receptor and is cleaved by TMPRSS2. However, whether S mutations affect SARS-CoV-2 cell entry remains unknown. Here, we show that naturally occurring S mutations can reduce or enhance cell entry via ACE2 and TMPRSS2. A SARS-CoV-2 S-pseudotyped lentivirus exhibits substantially lower entry than that of SARS-CoV S. Among S variants, the D614G mutant shows the highest cell entry, as supported by structural and binding analyses. Nevertheless, the D614G mutation does not affect neutralization by antisera against prototypic viruses. Taken together, we conclude that the D614G mutation increases cell entry by acquiring higher affinity to ACE2 while maintaining neutralization susceptibility. Based on these findings, further worldwide surveillance is required to understand SARS-CoV-2 transmissibility among humans. Subject terms: SARS-CoV-2, Virus-host interactions INTRODUCTION The outbreak of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1–4 has rapidly spread around the globe, affecting more than 180 countries. During the COVID-19 pandemic, SARS-CoV-2 has accumulated mutations throughout viral genes encoding the ORF1a, ORF1b, ORF3, ORF8, nucleocapsid (N), S proteins, etc., some of which are clade-defining (Nextstrain, http://nextstrain.org/ncov, based on the GISAID data, www.gisaid.org). Mutations in the S protein are especially crucial because the S protein is key for the first step of viral transmission, i.e., entry into the cell by binding to the angiotensin-converting enzyme-2 (ACE2) receptor1, followed by cleavage with transmembrane protease serine 2 (TMPRSS2)5,6, both of which are abundantly expressed in not only the airways, lungs, and nasal/oral mucosa7,8 but also the intestines9. However, it remains unclear whether S mutations affect SARS-CoV-2 cell entry. In this study, we analyze ACE2/TMPRSS2 usage of SARS-CoV S and SARS-CoV-2 S (referred to hereafter as SARS-S and SARS2-S, respectively), compare cell entry of natural SARS2-S variants, and focus on the D614G variant by investigating its structure, ACE2-binding affinity, and neutralization susceptibility. Our results indicate that the D614G mutation confers increased entry efficiency resulting from enhanced binding affinity for ACE2 with no influence on the antigenicity of the S protein. RESULTS SARS2-S-mediated cell entry shows a strong dependence on TMPRSS2 expression To quantify S-mediated cell entry, we employed a novel normalization system for cell entry, which we have recently established by generating a lentiviral vector harboring a small luminescent peptide tag, HiBiT, allowing us to precisely normalize input virus doses. This system results in enhanced experimental accuracy in a single-round replication assay10 in which a small but detectable difference in cell entry on a linear scale is critical because such a difference can be amplified in multiple virus replication cycles. By using this system, we first examined the cell entry activity of lentiviruses pseudotyped with SARS-CoV (Urbani strain) S or SARS-CoV-2 (Wuhan-Hu-1 strain) S in cells expressing ACE2, a major receptor for SARS-S11. The lentivirus pseudotyped with SARS-S was able to efficiently enter 293T cells expressing ACE2, whereas the SARS2-S-pseudotyped virus entered the cells much less efficiently (Supplementary Fig. 1). This result suggests that the expression of ACE2 alone is insufficient to support cell entry of SARS-CoV-2. Because accumulated evidence has shown that the expression of TMPRSS2 enhances both SARS-CoV and SARS-CoV-2 infection5,6, we next tested whether the coexpression of ACE2 and TMPRSS2 could mediate efficient infection of 293T cells with SARS2-S-pseudotyped lentiviruses. Notably, the dual expression of ACE2 and TMPRSS2 markedly facilitated SARS2-S-mediated cell entry while moderately enhancing entry by the SARS-S pseudovirus (Fig. 1a). These results indicate that SARS2-S-mediated entry into cells is more highly dependent on TMPRSS2 coexpression than that of SARS-CoV, suggesting that they may have different cellular tropisms to some extent. [Figure: SARS2-S-mediated cell entry is highly dependent on TMPRSS2.a Viruses were prepared by transfection of 293T cells with the HiBiT-tagged lentiviral packaging plasmid, the firefly luciferase-reporter lentiviral transfer plasmid, and either a SARS-CoV S (SARS-S) or SARS-CoV-2 S (SARS2-S) expression plasmid. Viral supernatants were subjected to HiBiT assays, and S-pseudotyped viruses normalized by HiBiT activity were used for infection of 293T cells expressing the host receptor ACE2 alone (black) or coexpressing TMPRSS2 (gray). Cell entry was determined by firefly luciferase activity in cell lysates. Data from four experiments are shown as a percentage of cell entry of SARS-S-pseudotyped viruses into 293T cells expressing ACE2 only (mean ± s.d., n = 3 technical replicates). The p value was calculated using a two-tailed paired or unpaired Student’s t-test. b, c The effect of ACE2 or TMPRSS2 expression levels on cell entry activity. 293T cells were transfected with a high and constant level of an expression plasmid encoding ACE2 together with increasing levels of a TMPRSS2 expression plasmid (b), and vice versa (c). Transfected cells were infected with lentiviruses pseudotyped with either SARS-S (circle) or SARS2-S (square), as described in a. Data shown are representative of three independent experiments (mean ± s.d., n = 3 technical replicates). Source data are provided as a Source Data file.] Nevertheless, ~25-fold differences in cell entry between SARS-S and SARS2-S pseudoviruses were observed (Fig. 1a), leading to the hypothesis that SARS2-S might be less compatible with lentiviral particles. Because a large body of literature has shown that lentiviral compatibility of a variety of viral envelopes is determined by their cytoplasmic tail (CT) domains12–14, we compared the sequences of this domain (as well as the transmembrane (TM) domain) in S proteins and found that SARS2-S has one (alanine-to-cysteine at position 1247) and two (valine-to-isoleucine at position 1216 and leucine-to-methionine at position 1233) amino acid differences in the CT and TM domains, respectively (Supplementary Fig. 2a). Thus, we created a SARS2-S C1247A mutant and a chimeric SARS2-S harboring the TM/CT domains of SARS-S. All SARS2-S proteins showed comparable levels of cell entry (Supplementary Fig. 2b) and actual virion incorporation (Supplementary Fig. 2c). These results suggest that the significantly lower rate of cell entry of the SARS2-S pseudovirus was not due to the incompatibility between SARS2-S and a lentiviral vector but rather to the intrinsic nature of the SARS2-S protein. To further assess differences between the SARS-S and SARS2-S proteins, we next addressed whether these S proteins might differ in their ability to utilize a given level of cell-surface ACE2 or TMPRSS2. Based on lentiviral infection of 293T cells expressing a high and constant level of ACE2 together with a range of expression levels of TMPRSS2 and vice versa (Fig. 1b, c), SARS2-S-mediated infection required higher levels of cell-surface TMPRSS2 expression than SARS-S to attain maximum levels of cell entry. Therefore, it is likely that SARS2-S essentially requires sufficient levels of TMPRSS2 expression. SARS2-S D614G variant displays highest entry efficiency among natural S variants Next, we investigated using our assay system whether naturally occurring mutations in the S protein affect the cell entry of SARS-CoV-2. We created plasmids expressing five different S variants that were initially identified in China (H49Y15), Europe (V367F16 and D614G17–19), and the United States (G476S and V483A16) (Fig.